gefitinib has been researched along with Pituitary ACTH Hypersecretion in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feelders, RA; Hofland, LJ; Lacroix, A; Newell-Price, J; Nieman, LK; Pivonello, R | 1 |
| Ben-Shlomo, A; Bruyette, D; Cooper, O; Fukuoka, H; Mamelak, A; Melmed, S; Ren, SG | 1 |
1 review(s) available for gefitinib and Pituitary ACTH Hypersecretion
| Article | Year |
|---|---|
Advances in the medical treatment of Cushing's syndrome.
Topics: ACTH Syndrome, Ectopic; ACTH-Secreting Pituitary Adenoma; Adenoma; Adrenal Gland Neoplasms; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cabergoline; Cushing Syndrome; Dopamine Agonists; ErbB Receptors; Gefitinib; Hormones; Humans; Imidazoles; Isoquinolines; Molecular Targeted Therapy; Pituitary ACTH Hypersecretion; Pyrazoles; Pyridines; Receptors, Glucocorticoid; Roscovitine; Somatostatin; Temozolomide; Tretinoin | 2019 |
1 other study(ies) available for gefitinib and Pituitary ACTH Hypersecretion
| Article | Year |
|---|---|
EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adrenocorticotropic Hormone; Animals; Cell Line, Tumor; Corticosterone; Dog Diseases; Dogs; Drug Screening Assays, Antitumor; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Molecular Targeted Therapy; Neoplasm Transplantation; Pituitary ACTH Hypersecretion; Pro-Opiomelanocortin; Promoter Regions, Genetic; Protein Kinase Inhibitors; Quinazolines; Secretory Rate; Tumor Burden | 2011 |